Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$292.40
-0.7%
$276.27
$190.75
▼
$302.93
$516.85B0.26.28 million shs3.70 million shs
Amgen Inc. stock logo
AMGN
Amgen
$457.93
-0.9%
$425.81
$312.39
▼
$483.99
$247.70B0.432.75 million shs2.03 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.63
+16.4%
$1.18
$0.56
▼
$2.72
$179.59M1.714.95 million shs15.55 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$206.80
-3.9%
$203.06
$22.28
▼
$280.80
$83.68B1.1612.53 million shs8.20 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.34%+0.45%+3.11%+13.58%+26.57%
Amgen Inc. stock logo
AMGN
Amgen
-0.72%-0.63%+6.90%+8.71%+37.29%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.10%-7.28%+41.40%+16.67%-31.71%
Moderna, Inc. stock logo
MRNA
Moderna
-3.63%-19.97%-1.26%+241.92%+769.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$292.40
-0.7%
$276.27
$190.75
▼
$302.93
$516.85B0.26.28 million shs3.70 million shs
Amgen Inc. stock logo
AMGN
Amgen
$457.93
-0.9%
$425.81
$312.39
▼
$483.99
$247.70B0.432.75 million shs2.03 million shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.63
+16.4%
$1.18
$0.56
▼
$2.72
$179.59M1.714.95 million shs15.55 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$206.80
-3.9%
$203.06
$22.28
▼
$280.80
$83.68B1.1612.53 million shs8.20 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.34%+0.45%+3.11%+13.58%+26.57%
Amgen Inc. stock logo
AMGN
Amgen
-0.72%-0.63%+6.90%+8.71%+37.29%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.10%-7.28%+41.40%+16.67%-31.71%
Moderna, Inc. stock logo
MRNA
Moderna
-3.63%-19.97%-1.26%+241.92%+769.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$297.851.59% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.30
Hold$425.69-7.25% Downside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$6.33307.29% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$120.25-41.12% Downside

Current Analyst Ratings Breakdown

Latest ABBV, MRNA, AMGN, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$102.00
11/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$95.00 ➝ $200.00
11/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$325.00 ➝ $335.00
11/16/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetEqual Weight$400.00 ➝ $430.00
11/12/2026
Amgen Inc. stock logo
AMGN
Amgen
Boost Price TargetBuy$460.00 ➝ $515.00
11/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$5.00
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingSell (E+)
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingOverweight$8.00 ➝ $6.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingOverweight$230.00 ➝ $305.00
11/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$137.00 ➝ $195.00
11/6/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$3.00 ➝ $8.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$66.01B7.85$15.08 per share19.44($2.57) per share-114.08
Amgen Inc. stock logo
AMGN
Amgen
$36.75B6.76$33.21 per share13.82$26.53 per share17.30
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K2,855.50N/AN/A($0.31) per share-5.02
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B42.51N/AN/A$16.90 per share12.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$5.8150.4818.301.3415.67%-450.55%16.50%2/3/2027 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$17.2426.6318.333.2524.14%114.99%13.47%2/2/2027 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.54N/AN/AN/AN/A-28,886.30%-75.67%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.10N/AN/AN/A-110.46%-25.79%-15.85%N/A

Latest ABBV, MRNA, AMGN, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2067-$0.50-$0.2933-$0.50$2.27 million$0.30 million
11/6/2026Q3 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$1.10$0.38+$1.48$0.38$890.25 million$1.31 billion
11/3/2026Q3 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.79$6.45+$0.66$7.08$10.07 billion$10.37 billion
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.73$3.82+$0.09$2.37$17.32 billion$17.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$7.282.47%+6.80%125.30%53 Years
Amgen Inc. stock logo
AMGN
Amgen
$10.082.18%+8.27%58.47%14 Years
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ABBV, MRNA, AMGN, and INO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.822.47%1/15/20271/15/20272/16/2027
10/27/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.25%11/20/202611/20/202612/11/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.87
0.75
Amgen Inc. stock logo
AMGN
Amgen
3.60
1.48
1.20
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
0.57
1.00
Moderna, Inc. stock logo
MRNA
Moderna
0.52
3.62
3.47

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.91 million536.31 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112110.18 million108.31 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700404.62 million360.92 millionOptionable

Recent News About These Companies

At $215, Moderna Stock Already Prices In A Comeback
Moderna Stock: What the Company Does and What Drives the Shares
Moderna (NASDAQ:MRNA) Stock Falls 3.6% - What's Next?
Top Biotech Stocks To Consider - November 16th
Top Biotech Stocks To Add to Your Watchlist - November 15th
Aberdeen Group plc Buys 1,039,311 Shares of Moderna, Inc. $MRNA
Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?
The Single Most Important Metric For Moderna Stock
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
Promising Biotech Stocks To Consider - November 13th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$292.40 -2.15 (-0.73%)
Closing price 03:59 PM Eastern
Extended Trading
$292.26 -0.14 (-0.05%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen stock logo

Amgen NASDAQ:AMGN

$457.93 -4.39 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$454.32 -3.61 (-0.79%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.63 +0.23 (+16.43%)
Closing price 04:00 PM Eastern
Extended Trading
$1.66 +0.03 (+1.53%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna stock logo

Moderna NASDAQ:MRNA

$206.80 -8.47 (-3.93%)
Closing price 04:00 PM Eastern
Extended Trading
$206.04 -0.76 (-0.37%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.